



Toxicological Profile for 1,2-Dichloroethene

Draft for Public Comment

August 2023



U.S. Department of Health and Human Services
Agency for Toxic Substances and Disease Registry

DISCLAIMER

Use of trade names is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry, the Public Health Service, or the U.S. Department of Health and Human Services.

This information is distributed solely for the purpose of pre dissemination public comment under applicable information quality guidelines. It has not been formally disseminated by the Agency for Toxic Substances and Disease Registry. It does not represent and should not be construed to represent any agency determination or policy.

FOREWORD

This toxicological profile is prepared in accordance with guidelines developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for these toxic substances described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a substance's toxicologic properties. Other pertinent literature is also presented but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a relevance to public health discussion which would allow a public health professional to make a real-time determination of whether the presence of a particular substance in the environment poses a potential threat to human health. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to the protection of public health are identified by ATSDR and EPA.

Each profile includes the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a toxic substance to ascertain the levels of significant human exposure for the substance and the associated acute, intermediate, and chronic health effects;
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine the levels of exposure that present a significant risk to human health due to acute, intermediate, and chronic duration exposures; and
- (C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public. ATSDR plans to revise these documents in response to public comments and as additional data become available. Therefore, we encourage comments that will make the toxicological profile series of the greatest use.

Electronic comments may be submitted via: www.regulations.gov. Follow the on-line instructions for submitting comments.

Written comments may also be sent to: Agency for Toxic Substances and Disease Registry
Office of Innovation and Analytics
Toxicology Section
1600 Clifton Road, N.E.
Mail Stop S106-5
Atlanta, Georgia 30329-4027

The toxicological profiles are developed under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund). CERCLA section 104(i)(1) directs the Administrator of ATSDR to "...effectuate and implement the health related authorities" of the statute. This includes the preparation of toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List (NPL) and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list. In addition, ATSDR has the authority to prepare toxicological profiles for substances not found at sites on the NPL, to "...establish and maintain inventory of literature, research, and studies on the health effects of toxic substances" under CERCLA Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and as otherwise necessary to support the site-specific response actions conducted by ATSDR.

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staffs of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and is being made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.

Aaron Bernstein, M.D., M.P.H.
Director, National Center for Environmental Health and
Agency for Toxic Substances and Disease Registry,
Centers for Disease Control and Prevention

Christopher M. Reh, Ph.D.
Associate Director
Agency for Toxic Substances and Disease Registry
Centers for Disease Control and Prevention

VERSION HISTORY

Date	Description
August 2023	Draft for public comment toxicological profile released
August 1996	Final toxicological profile released

CONTRIBUTORS & REVIEWERS

CHEMICAL MANAGER TEAM

Malcolm Williams, D.V.M., Ph.D. (Lead)
Gaston Casillas, Ph.D.
Sam Keith, M.S., C.H.P.
Mike Fay, Ph.D.

Julie M. Klotzbach, Ph.D.
Mario Citra, Ph.D.

ATSDR, Office of Innovation and Analytics,
Toxicology Section, Atlanta, GA

SRC, Inc., North Syracuse, NY

REVIEWERS

Interagency Minimal Risk Level Workgroup:

Includes ATSDR; National Center for Environmental Health (NCEH); National Institute for Occupational Safety and Health (NIOSH); U.S. Environmental Protection Agency (EPA); National Toxicology Program (NTP).

Additional reviews for science and/or policy:

ATSDR, Office of Community Health Hazard Assessment; ATSDR, Office of Capacity Development and Applied Prevention Science; ATSDR, Office of Science; NCEH, Division of Laboratory Sciences; NCEH, Division of Environmental Health Science and Practice; EPA.

PEER REVIEWERS

1. Mary Beth Genter, Ph.D; Professor; Department of Environmental Health; University of Cincinnati; Cincinnati, Ohio.
2. Matt Simcik, Ph.D.; Professor; Division of Environmental Health Sciences; School of Public Health; University of Minnesota; Minneapolis, Minnesota.
3. G.A. Shakeel Ansari, Ph.D.; Professor; Department of Pathology; University of Texas Medical Branch; Galveston, Texas.

These experts collectively have knowledge of toxicology, chemistry, and/or health effects. All reviewers were selected in conformity with Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

ATSDR scientists review peer reviewers' comments and determine whether changes will be made to the profile based on comments. The peer reviewers' comments and responses to these comments are part of the administrative record for this compound.

The listing of peer reviewers should not be understood to imply their approval of the profile's final content. The responsibility for the content of this profile lies with ATSDR.

CONTENTS

DISCLAIMER	ii
FOREWORD	iii
VERSION HISTORY	v
CONTRIBUTORS & REVIEWERS	vi
CONTENTS.....	vii
LIST OF FIGURES	ix
LIST OF TABLES.....	x
CHAPTER 1. RELEVANCE TO PUBLIC HEALTH	1
1.1 OVERVIEW AND U.S. EXPOSURES	1
1.2 SUMMARY OF HEALTH EFFECTS.....	1
1.3 MINIMAL RISK LEVELS (MRLs)	6
CHAPTER 2. HEALTH EFFECTS.....	9
2.1 INTRODUCTION.....	9
2.2 DEATH	46
2.3 BODY WEIGHT	47
2.4 RESPIRATORY	49
2.5 CARDIOVASCULAR	50
2.6 GASTROINTESTINAL.....	50
2.7 HEMATOLOGICAL	51
2.8 MUSCULOSKELETAL	53
2.9 HEPATIC	54
2.10 RENAL	56
2.11 DERMAL	57
2.12 OCULAR.....	58
2.13 ENDOCRINE	59
2.14 IMMUNOLOGICAL.....	59
2.15 NEUROLOGICAL	61
2.16 REPRODUCTIVE	62
2.17 DEVELOPMENTAL.....	63
2.18 OTHER NONCANCER	64
2.19 CANCER	65
2.20 GENOTOXICITY	66
2.21 MECHANISM OF TOXICITY	71
CHAPTER 3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS	72
3.1 TOXICOKINETICS.....	72
3.1.1 Absorption.....	73
3.1.2 Distribution	74
3.1.3 Metabolism.....	74
3.1.4 Excretion	77
3.1.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models	77
3.1.6 Animal-to-Human Extrapolations	79
3.2 CHILDREN AND OTHER POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE.....	80
3.3 BIOMARKERS OF EXPOSURE AND EFFECT	81
3.3.1 Biomarkers of Exposure.....	82
3.3.2 Biomarkers of Effect	82

3.4	INTERACTIONS WITH OTHER CHEMICALS	82
CHAPTER 4. CHEMICAL AND PHYSICAL INFORMATION		83
4.1	CHEMICAL IDENTITY.....	83
4.2	PHYSICAL AND CHEMICAL PROPERTIES.....	83
CHAPTER 5. POTENTIAL FOR HUMAN EXPOSURE		86
5.1	OVERVIEW	86
5.2	PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL	87
5.2.1	Production	87
5.2.2	Import/Export.....	88
5.2.3	Use	88
5.2.4	Disposal.....	89
5.3	RELEASES TO THE ENVIRONMENT	90
5.3.1	Air	90
5.3.2	Water	92
5.3.3	Soil	93
5.4	ENVIRONMENTAL FATE	93
5.4.1	Transport and Partitioning.....	93
5.4.2	Transformation and Degradation	95
5.5	LEVELS IN THE ENVIRONMENT	98
5.5.1	Air	100
5.5.2	Water.....	103
5.5.3	Sediment and Soil	112
5.5.4	Other Media	112
5.6	GENERAL POPULATION EXPOSURE.....	113
5.7	POPULATIONS WITH POTENTIALLY HIGH EXPOSURES	115
CHAPTER 6. ADEQUACY OF THE DATABASE.....		116
6.1	Information on Health Effects	116
6.2	Identification of Data Needs.....	116
6.3	Ongoing Studies	125
CHAPTER 7. REGULATIONS AND GUIDELINES		126
CHAPTER 8. REFERENCES		130
APPENDICES		
APPENDIX A. ATSDR MINIMAL RISK LEVELS AND WORKSHEETS.....		A-1
APPENDIX B. LITERATURE SEARCH FRAMEWORK FOR 1,2-DICHLOROETHENE.....		B-1
APPENDIX C. FRAMEWORK FOR ATSDR'S SYSTEMATIC REVIEW OF HEALTH EFFECTS DATA FOR 1,2-DICHLOROETHENE		C-1
APPENDIX D. USER'S GUIDE.....		D-1
APPENDIX E. QUICK REFERENCE FOR HEALTH CARE PROVIDERS		E-1
APPENDIX F. GLOSSARY		F-1
APPENDIX G. ACRONYMS, ABBREVIATIONS, AND SYMBOLS.....		G-1

LIST OF FIGURES

1-1. Health Effects Found in Animals Following Inhalation Exposure to trans-1,2-Dichloroethene.....	3
1-2. Health Effects Found in Animals Following Oral Exposure to trans-1,2-Dichloroethene.....	3
1-3. Summary of Sensitive Targets of trans-1,2-Dichloroethene – Inhalation	6
1-4. Summary of Sensitive Targets of trans-1,2-Dichloroethene – Oral	7
2-1. Overview of the Number of Studies Examining trans-1,2-Dichloroethene Health Effects.....	12
2-2. Overview of the Number of Studies Examining cis-1,2-Dichloroethene Health Effects.....	13
2-3. Overview of the Number of Studies Examining Mixtures of trans- and cis-1,2-Dichloroethene Health Effects	14
2-4. Levels of Significant Exposure to trans-1,2-Dichloroethene – Inhalation	17
2-5. Levels of Significant Exposure to trans-1,2-Dichloroethene – Oral.....	26
2-6. Levels of Significant Exposure to cis-1,2-Dichloroethene – Oral.....	36
2-7. Levels of Significant Exposure to Mixtures of cis- and trans-1,2-Dichloroethene – Inhalation	44
3-1. Postulated Metabolic Scheme for 1,2-Dichloroethene	75
5-1. Number of NPL Sites with 1,2-Dichloroethene Contamination.....	86
6-1. Summary of Existing Health Effects Studies on trans-1,2-Dichloroethene by Route and Endpoint	117
6-2. Summary of Existing Health Effects Studies on cis-1,2-Dichloroethene by Route and Endpoint	118
6-3. Summary of Existing Health Effects Studies for Mixtures of trans- and cis-1,2-Dichloroethene by Route and Endpoint	119

LIST OF TABLES

1-1. Minimal Risk Levels (MRLs) for trans-1,2-Dichloroethene	8
1-2. Minimal Risk Levels (MRLs) for cis-1,2-Dichloroethene	8
2-1. Levels of Significant Exposure to trans-1,2-Dichloroethene – Inhalation	15
2-2. Levels of Significant Exposure to trans-1,2-Dichloroethene – Oral.....	21
2-3. Levels of Significant Exposure to trans-1,2-Dichloroethene – Dermal.....	33
2-4. Levels of Significant Exposure to cis-1,2-Dichloroethene – Oral.....	34
2-5. Levels of Significant Exposure to Mixtures of cis- and trans-1,2-Dichloroethene – Inhalation	42
2-6. Genotoxicity of cis- and trans-1,2-Dichloroethene <i>In Vivo</i>	66
2-7. Genotoxicity of cis- and trans-1,2-Dichloroethene <i>In Vitro</i>	67
3-1. Optimized Values for Metabolism Parameters in the Lilly et al. (1998) Rat PBPK Model of 1,2-Dichloroethene	77
4-1. Chemical Identity of Isomers of 1,2-Dichloroethene	84
4-2. Physical and Chemical Properties of cis- and trans-1,2-Dichloroethene.....	85
5-1. Facilities that Produce, Process, or Use 1,2-Dichloroethene	88
5-2. Releases to the Environment from Facilities that Produce, Process, or Use 1,2-Dichloro- ethene.....	90
5-3. Lowest Limit of Detection for 1,2-Dichloroethene Based on Standards.....	99
5-4. 1,2-Dichloroethene, cis-1,2-Dichloroethene, and trans-1,2-Dichloroethene Levels in Water, Soil, and Air of National Priorities List (NPL) Sites.....	99
5-5. Summary of Annual Concentration of cis-1,2-Dichloroethene (ppbv) Measured in Ambient Air at Locations Across the United States.....	100
5-6. Historical Air Monitoring Data for 1,2-Dichloroethene in the United States.....	101
5-7. Water Monitoring Data for 1,2-Dichloroethene	104
5-8. Levels of trans-1,2-Dichloroethene in FDA Total Diet Studies	113
7-1. Regulations and Guidelines Applicable to 1,2-Dichloroethene.....	126